This Stock Is Up 440% in a Year. Is It an Undiscovered Star or a Flash in the Pan?

• Nanobiotix (NBTX) is a clinical-stage nanomedicine company showing exceptional price momentum and technical strength.
• Shares are trading at new all-time highs.
• NBTX has surged 440% over the past year.
• Nanobiotix has a Trend Seeker “Buy” signal and strong technical indicators, but it remains highly volatile.  

Today’s Featured Stock

Valued at $1.3 billion, Nanobiotix (NBTX) is a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer. The company’s proprietary technology includes NBTXR3.  

What I’m Watching

I found today’s Chart of the Day by using Barchart’s powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction; and a Trend Seeker “buy” signal. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. NBTX checks those boxes. Since the Trend Seeker signaled a new “Buy” on Aug. 27, the stock has gained 200.78%.

NBTX Price vs Daily Moving Averages:

Barchart Technical Indicators for Nanobiotix

Editor’s Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. These technical indicators form the Barchart Opinion on a particular stock.

NBTX hit an all-time high of $27.77 in intraday trading on Oct. 8.

• NBTX has a Weighted Alpha of +470.88.
• Nanobiotix has an 100% “Buy” opinion from Barchart.
• The stock gained 439.50% over the past year.
• NBTX has its Trend Seeker “Buy” signal intact.
• Nanobiotix has made 13 new highs and gained 198.02% in the last month.
• Relative Strength Index (RSI) is at 82.55.
• There’s a technical support level around $25.96.

Don’t Forget the Fundamentals

• $1.3 billion market capitalization.
• Revenue is projected to grow 643.31% this year and another 89.01% next year.
• Earnings are estimated to increase by 79.86% this year and an additional 235.61% next year.

Analyst and Investor Sentiment on Nanobiotix

I don’t buy stocks because everyone else is buying, but I do realize that if major firms and investors are dumping stock, it’s hard to make money swimming against the tide.

It looks like Wall Street analysts have discovered NBTX but no one else has.

• The Wall Street analysts tracked by Barchart have issued 4 “Strong Buy” and 2 “Hold” opinions on the stock with price targets between $3.50 and $24.00, an extremely wide range.
• Value Line and CFRA’s MarketScope Advisor do not rate the stock yet.
• Morningstar thinks the stock is 6% overvalued.
• Of the 240,000 investors following stocks on Motley Fool, none have rated NBTX.
• 954 investors monitor the stock on Seeking Alpha, which rates the stock a “Hold” and comments: “Nanobiotix’s recent Phase 1 data for NBTXR3 in anti-PD-1 resistant melanoma showed promising results with high response and disease control rates, boosting investor confidence in the company's potential market value.”

The Bottom Line on Nanobiotix

Analysts project growth in revenue and earnings for Nanobiotix, and the company has an emerging following by Wall Street analysts. Investors should note the stock’s volatility and employ disciplined risk management.

At this point NBTX is a speculative opportunity and needs time to prove it can increase Revenue and Earnings.

Today’s Chart of the Day was written by Jim Van Meerten. Read previous editions of the daily newsletter here.

Additional disclosure: The Barchart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance.